Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Biosciences Raises $21.75M in Private Financing

NEW YORK (GenomeWeb News) – Predictive Biosciences has closed a Series B financing that has brought in $21.75 million in funding, the Lexington, Mass.-based company said today.
Predictive Bio is developing biomarker-based assays for a variety of cancers, with an initial focus on bladder cancer. The firm also is looking into developing tests for breast, ovarian, prostate, and colorectal cancers.
Predictive Bio said the funds would be used to complete current clinical validation studies and initiate multi-center clinical trials. It also said proceeds would fund efforts to open a CLIA-compliant lab to run diagnostic tests.
The financing round was led by New Enterprise Associates and included Kaiser Permanente Ventures, as well investors from its $10 million Series A round including Flybridge Capital Partners and Highland Capital Partners.
In conjunction with the most recent financing, NEA General Partner James Barrett has joined Predictive Bio’s board of directors, and Kaiser Permanente Ventures Senior Venture Manager Jordan Kramer has been named a board observer.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.